Gastrointestinal lymphomas

Czech version

Authors: P. Klener ^1,2
Authors‘ workplace: I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta doc. MUDr. Marek Trněný, CSc., 2 ÚHKT Praha, zastupující ředitel prof. Ing. Jan E. Dyr, DrSc. ¹
Published in: Vnitř Lék 2009; 55(Suppl 1)(Supplementum 1): 74-76

Overview

Gatrointestinal tract is the most commonly affected site of extranodal non‑Hodgkin’s lymphomas (NHL) accounting for approximately 40% of all extranodal primary NHL. Almost a half of them are indolent lymphomas, mainly MALT lymphoma. From agressive forms is the most frequent difuse large cell B‑lymphoma (DLCBL). In this review, principles of diagnostic and treatment of gastrointestinal lymphomas are presented.

Key words:
malignant lymphoma –⁠ extranodal forms –⁠ Helicobacter pylori –⁠ MALT

Sources

1. Chan JKC. Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems. Semin Diagn Pathol 1996; 13 : 260–296.

2. Magrath I. The non‑Hodgkin’s lymphoma. London: Arnold 1997.

3. Zemsky L, Katz H, Edelman M et al. Hodgkin’s disease involving large bowel. Clin Colorectal Cancer 2001; 1 : 185–186.

4. Isaacson PG, Bortin AJ. Extranodal lymphomas. New York: Churchill Livingstone 2004.

5. Morgner A, Beverdorffer E, Neubauer A et al. Malignant tumors of the stomach: Gastric mucosa‑associated lymphoid tissue lymphoma and Helicobacter pylori. Gastroenterol Clin North A 2000; 29 : 593–607.

6. Salem PA, Estehan FF. Immunoproliferative small intestinal disease: current concepts. Cancer J 2005; 11 : 374–382.

7. Peters J, Rondonotti E, Weljmer MC et al. Lymphomatous polyposis of the small intestine. Gastrointest.Endosc 2008; 67 : 763–765.

8. Maral M, Demirpence M, Gonen C et al. Difuse gastrointestinal involvement of mantle cell lymphoma. Turk J Gastroenterol 2008; 19 : 117–120.

9. Santacroce L, Cagiano B, Del Prete R et al. Helicobacter pylori infection and gastric MALTomas: an up-to-date and therapy highlight. Clin Ter 2008; 159 : 457–462.

10. Trněný M, Klener P. Deset let od úspěšného zavedení prvé monoklonální protilátky (rituximab) do léčby lymfomů. Čas Lék Čes 2007; 146 : 578–585.